Sorafenib

Catalog No.S7397 Synonyms: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 199 Publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NG\wUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\6O4RPUUN3ME2wMlAxODByM{CzJO69VQ>? M2noTnNCVkeHUh?=
MONO-MAC-6 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\abYdKSzVyPUCuNFA1OThizszN NIfUWFRUSU6JRWK=
ALL-PO M4DucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LlZ2lEPTB;MD6wN|E5PCEQvF2= MW\TRW5ITVJ?
NKM-1 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\kTWM2OD1yLkC3OFE3KM7:TR?= NIn6cG1USU6JRWK=
CGTH-W-1 M4PtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\le2lEPTB;MD6yOVAzOiEQvF2= MVzTRW5ITVJ?
BB65-RCC NX\RbYNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WwZ2lEPTB;MD60O|A4OyEQvF2= MnrIV2FPT0WU
NOS-1 M4THfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37qeGlEPTB;MD61OlM3KM7:TR?= M4m5XXNCVkeHUh?=
SH-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHexSmtKSzVyPUCuOlU3OTNizszN NH7pcolUSU6JRWK=
HOP-62 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwOEWwPFgh|ryP NWTJUo1lW0GQR1XS
HCC2998 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nCUGlEPTB;MD64PFgyQCEQvF2= NUTtS2p2W0GQR1XS
GDM-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjlTWM2OD1yLkmwOlk5KM7:TR?= MmLMV2FPT0WU
KM12 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwMEKwPVgh|ryP M1fCW3NCVkeHUh?=
LB2518-MEL NWrWfFg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\WTWM2OD1zLkKwPFA6KM7:TR?= NFjkS49USU6JRWK=
NCI-H1436 M375Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\TRXlKSzVyPUGuNlE3PzhizszN MUHTRW5ITVJ?
EM-2 M1qydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\KTWM2OD1zLkO1OVc5KM7:TR?= M4nzcHNCVkeHUh?=
LAMA-84 M{jXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwM{e2OFgh|ryP M4i5WnNCVkeHUh?=
KG-1 M3WxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zQXWlEPTB;MT60O|k{PSEQvF2= MWjTRW5ITVJ?
A388 MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwNUmxOlUh|ryP M1r1SnNCVkeHUh?=
no-10 M1\qbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwNkG3NlYh|ryP NFPPfFRUSU6JRWK=
SF126 M4nN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnzTWM2OD1zLk[zPFEzKM7:TR?= NUfyRYpYW0GQR1XS
MEG-01 NYjYfo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrHTWM2OD1zLkiwPVgh|ryP NVfLOJc{W0GQR1XS
A3-KAW NFPZb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zmRmlEPTB;MT64PFQzKM7:TR?= M1HxUnNCVkeHUh?=
D-247MG M4C0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLN[oNKSzVyPUKuNVQ1QCEQvF2= M2XOSHNCVkeHUh?=
OVCAR-4 NGLEcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;FT2dKSzVyPUKuNlE{QTNizszN MUfTRW5ITVJ?
NCI-SNU-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjITWM2OD1{LkOxOlIh|ryP MXPTRW5ITVJ?
NCI-H2171 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPwTWM2OD1{LkO5O|Y1KM7:TR?= M3vKOnNCVkeHUh?=
SIG-M5 NYTXSWkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTo[ZBvUUN3ME2yMlQzOjR{IN88US=> NWC5TWpNW0GQR1XS
BE-13 NX;vZ2U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XQcGlEPTB;Mj62PVYxQSEQvF2= MmnuV2FPT0WU
K052 NIDJc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDyTWM2OD1{Lke0OlE3KM7:TR?= NWTNZ4VRW0GQR1XS
L-540 NFHJdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zRSGlEPTB;Mj63OVc5QSEQvF2= MkXrV2FPT0WU
KMOE-2 NILCT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwOEGzOUDPxE1? MnfDV2FPT0WU
MFH-ino NHfUT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwOUKxPFUh|ryP MWjTRW5ITVJ?
HL-60 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fob2lEPTB;Mz6wOlI6QSEQvF2= M4nTXHNCVkeHUh?=
HCC2218 NEOzW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqyUGZKSzVyPUOuNVIxODNizszN NWD1RWpsW0GQR1XS
TE-5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLwNFBKSzVyPUOuNVMyPjJizszN NV;x[pdpW0GQR1XS
MZ1-PC NVXEU2RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLFWFBKSzVyPUOuOFc2ODlizszN Mme1V2FPT0WU
MRK-nu-1 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNwNkG0Olgh|ryP NH;kRWFUSU6JRWK=
MZ7-mel M2W4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNwNk[wPVkh|ryP M4DUb3NCVkeHUh?=
BC-1 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Ttd2lEPTB;Mz63OFAzKM7:TR?= NIr6PXZUSU6JRWK=
ST486 M4TTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnwNJZWUUN3ME2zMlg{Pjd|IN88US=> NUfTUGxvW0GQR1XS
KS-1 NHiyV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDETWM2OD1|Lki4NVk5KM7:TR?= NET1TJhUSU6JRWK=
SK-NEP-1 Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTRwMU[4NVUh|ryP M4r1ZXNCVkeHUh?=
BC-3 NIfrSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRwMkOzPVEh|ryP NHj0NlJUSU6JRWK=
NCI-H1581 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTL[GprUUN3ME20MlI5Pzl6IN88US=> NICz[oRUSU6JRWK=
MHH-PREB-1 MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETwSXdKSzVyPUSuOFA1QDRizszN NUjyZVh6W0GQR1XS
NOMO-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DOeGlEPTB;ND60PFkxPSEQvF2= NGDoelNUSU6JRWK=
QIMR-WIL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP5UnpLUUN3ME21MlA4Ojl2IN88US=> NXrRPHh5W0GQR1XS
SF539 M3j3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fGRmlEPTB;NT6xN|IzPyEQvF2= NVnqbFJ3W0GQR1XS
TE-12 NWe2NWRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK5TWM2OD13LkK0PVI6KM7:TR?= NHLFSndUSU6JRWK=
NCI-H510A NH[0cm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7XTWM2OD13LkSxOlg2KM7:TR?= MoK4V2FPT0WU
JAR NU\UN|g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTVwNUC4NlQh|ryP NEj4RmRUSU6JRWK=
no-11 M3q3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLh[Wo{UUN3ME21Mlc{PTZ6IN88US=> NVHhOJdMW0GQR1XS
BV-173 NV\2R|V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXFXpNNUUN3ME21Mlk2Pjh{IN88US=> MV;TRW5ITVJ?
SR M2TiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTZwMEC2O|gh|ryP NILBOXJUSU6JRWK=
MOLT-16 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfPTWM2OD14LkK1NlY3KM7:TR?= M1OxOHNCVkeHUh?=
MZ2-MEL NVT3[2ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTZwM{G4N|kh|ryP NV;1NWhtW0GQR1XS
SW954 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm1ZWFQUUN3ME22MlQ2QDZ4IN88US=> M3vYZnNCVkeHUh?=
ML-2 NVuwcXB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:wUWZnUUN3ME22MlUzQDR7IN88US=> NGnQUXlUSU6JRWK=
OCI-AML2 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPwbWtKSzVyPU[uOlExPjJizszN NXjheJVYW0GQR1XS
SIMA NVL3OIduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXacWlEUUN3ME23MlAxOTBzIN88US=> NEPJZWpUSU6JRWK=
DOHH-2 NXHmW2w{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL6TWM2OD15LkC1Olc3KM7:TR?= NYLK[|g6W0GQR1XS
697 M1r3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTdwMEW5PFkh|ryP NGnPWGpUSU6JRWK=
NB1 M4TpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TnV2lEPTB;Nz60NFQxPyEQvF2= MXzTRW5ITVJ?
D-392MG NV3weWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTdwNkK2OlMh|ryP Mk\zV2FPT0WU
ES8 NVf6dGJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHR[XNKSzVyPUeuO|Y2ODNizszN MUTTRW5ITVJ?
RPMI-8226 M3\tfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDabGpKSzVyPUeuPFQ2OTFizszN NIXr[oZUSU6JRWK=
IST-MEL1 NGPGTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn0[FlKSzVyPUiuOFAxODJizszN NV;TW5I4W0GQR1XS
NB14 M{Ds[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTGOmhKSzVyPUiuOlMyOzNizszN M4TFVnNCVkeHUh?=
HD-MY-Z MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHqdHpCUUN3ME24MlY{PzR4IN88US=> M3OzTHNCVkeHUh?=
TE-10 NUXGfW53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGzfm5KSzVyPUiuO|Y{PTNizszN NIDFbm5USU6JRWK=
LC-1F NHL6[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu2TWM2OD17LkGwPFM1KM7:TR?= NUi5fZFCW0GQR1XS
OS-RC-2 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO2[JBmUUN3ME25MlEyOjR|IN88US=> MoL2V2FPT0WU
NCI-SNU-16 M{XLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTlwMkGwNlYh|ryP M3[wVXNCVkeHUh?=
SHP-77 NHHMR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS2TWM2OD17LkexOlYzKM7:TR?= NGjwdYNUSU6JRWK=
A4-Fuk NXnndohrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInHZplKSzVyPUmuO|U3OSEQvF2= NVSxVWFTW0GQR1XS
NB6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXTTWM2OD17Lke2NFI6KM7:TR?= MXfTRW5ITVJ?
JiyoyeP-2003 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7qTWM2OD1zMD60O|Q2KM7:TR?= NXTVbFc2W0GQR1XS
DMS-114 NXzHNGV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Lab2lEPTB;MUCuOVQ1OSEQvF2= MoPFV2FPT0WU
NB7 NWXne|lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHVfm06UUN3ME2xNE44PTJ4IN88US=> NUH2bHlJW0GQR1XS
NCI-H747 NV\MPG1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDTT4pkUUN3ME2xNU4yOjF4IN88US=> NX;2fW5wW0GQR1XS
HH NHHsV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF76W3BKSzVyPUGxMlM5PzZizszN NGHvUnFUSU6JRWK=
EW-18 NETxb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknGTWM2OD1zMT65NFQ1KM7:TR?= NH;CXnZUSU6JRWK=
CHP-126 M3TsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPTSVZKSzVyPUGxMlk4OzhizszN MULTRW5ITVJ?
NTERA-S-cl-D1 MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NESzc|JKSzVyPUGyMlAzPzhizszN MnnaV2FPT0WU
DEL NU[3U3l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\VUlVKSzVyPUGyMlA6QDVizszN NHz1TplUSU6JRWK=
LU-139 NXjWXo9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KxTGlEPTB;MUKuOVQyOyEQvF2= NXfh[5hDW0GQR1XS
P30-OHK Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLKV2FFUUN3ME2xNk42PDd7IN88US=> M3\0fHNCVkeHUh?=
NCI-H1522 NYHET5NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LsbmlEPTB;MUKuO|Q3KM7:TR?= NIfocHVUSU6JRWK=
NCI-H1299 NXPI[3VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ld2lEPTB;MUOuNlkyOSEQvF2= M1K3THNCVkeHUh?=
UACC-257 NYS1[3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF|LkWxNlYh|ryP MY\TRW5ITVJ?
Calu-6 M4\0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXJVIFFUUN3ME2xN{43ODR4IN88US=> NUL4PHNoW0GQR1XS
NCI-H1882 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF|Lki1OVUh|ryP M2DNTXNCVkeHUh?=
BB30-HNC M1jBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XxbWlEPTB;MUSuNFYxQSEQvF2= MYPTRW5ITVJ?
ES1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTF2LkG1OVEh|ryP Mo\QV2FPT0WU
NCI-H1694 NHnsTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPlRYtKSzVyPUG0MlQ5OTFizszN NF;xOo5USU6JRWK=
IST-SL1 NFjjXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF2Lkm2NVYh|ryP MmW2V2FPT0WU
ECC4 NFXxeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPZ[4M1UUN3ME2xOU4xPTV6IN88US=> MlWzV2FPT0WU
MDA-MB-134-VI NHjKOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\veVloUUN3ME2xOU41OTNzIN88US=> NVr0eol1W0GQR1XS
SCH NV31dZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\B[GhIUUN3ME2xOU41PzJ6IN88US=> NYLXd5lmW0GQR1XS
SK-N-FI MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi2VFNrUUN3ME2xOU43PTN2IN88US=> MV3TRW5ITVJ?
HDLM-2 NXy2c5M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\CeGlEPTB;MU[uNFcyPCEQvF2= M4TKeXNCVkeHUh?=
Ramos-2G6-4C10 NGLDWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfNcnk3UUN3ME2xOk4yOjl5IN88US=> NXG4TY51W0GQR1XS
EW-24 M{\hUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S2[mlEPTB;MU[uNVY3OSEQvF2= M3i5PXNCVkeHUh?=
NCI-H2141 NFvTemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK2TWM2OD1zNj6xPFkh|ryP MYXTRW5ITVJ?
LC4-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz4TWM2OD1zNj62NVE6KM7:TR?= MkLrV2FPT0WU
HT-144 NX\DXohYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTCW|ZlUUN3ME2xO{4xODZizszN MWfTRW5ITVJ?
SK-MEL-1 MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITsUoNKSzVyPUG3MlAxPzJizszN NGP0SYpUSU6JRWK=
SCC-15 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqzZ2NTUUN3ME2xO{4yPjN6IN88US=> MV\TRW5ITVJ?
C8166 M3K5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfpXpBmUUN3ME2xO{43QDN|IN88US=> NVzBV|RbW0GQR1XS
GOTO Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILINFhKSzVyPUG3Mlg{PDRizszN M4rjd3NCVkeHUh?=
COR-L279 NHnEZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF6LkGzOlIh|ryP MknyV2FPT0WU
K-562 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH2TWM2OD1zOD63NVQ{KM7:TR?= M2P5T3NCVkeHUh?=
ES3 M1vq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLpcVFKSzVyPUG4MlgxPDFizszN MmrkV2FPT0WU
LU-165 NISzenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF7LkewNFgh|ryP MlX5V2FPT0WU
KM-H2 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ITWM2OD1{MD6zNVg1KM7:TR?= M4GzOXNCVkeHUh?=
RL M3vlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofKTWM2OD1{MD65OlkzKM7:TR?= MmPEV2FPT0WU
EW-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXnTWM2OD1{MT6xPFg6KM7:TR?= NIfHbohUSU6JRWK=
A101D NGHkUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHroUmJKSzVyPUKxMlM4PTJizszN NXjJfG5DW0GQR1XS
HUTU-80 NVLWOmdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJzLkO5OFYh|ryP NEDmbI9USU6JRWK=
NCI-H23 M3Hw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJzLkO5PVIh|ryP NX;SdGRYW0GQR1XS
PF-382 NVTmfopLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3JepY3UUN3ME2yNU41PDB|IN88US=> MmLJV2FPT0WU
LB373-MEL-D NIjKTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP3[pVKSzVyPUKxMlU3OTVizszN MYTTRW5ITVJ?
TE-8 MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTyXYxKSzVyPUKxMlY{QTRizszN Mk\jV2FPT0WU
TE-9 MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJzLki1NVMh|ryP NGC0RVRUSU6JRWK=
Daudi NHy2NoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrlTWM2OD1{MT65N|A1KM7:TR?= M3vvdXNCVkeHUh?=
D-542MG Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfnTWM2OD1{Mj6wNlU3KM7:TR?= Mn\qV2FPT0WU
U-698-M M2O0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLLTWM2OD1{Mj60OlA{KM7:TR?= Mn7tV2FPT0WU
ES6 M1vBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjJOFFKSzVyPUKyMlc{PjZizszN NUHOOmU5W0GQR1XS
DU-4475 M2XaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF64fnNKSzVyPUKzMlg5QTdizszN M4DUTnNCVkeHUh?=
ECC12 M1;kfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WyR2lEPTB;MkSuNlgxOyEQvF2= Ml3DV2FPT0WU
C2BBe1 MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzSTWM2OD1{ND6zNlM6KM7:TR?= M3TrRnNCVkeHUh?=
IST-SL2 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ2LkSzOlIh|ryP MUjTRW5ITVJ?
DJM-1 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i2V2lEPTB;MkSuOVIzOSEQvF2= MW\TRW5ITVJ?
DMS-153 NYHQOYVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLtTWM2OD1{ND64OlE1KM7:TR?= M4HjbnNCVkeHUh?=
NB13 NFzKT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:ycpYyUUN3ME2yOU4xOjZ3IN88US=> M1TITHNCVkeHUh?=
SK-N-DZ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ4LkO0NVQh|ryP M{LsTHNCVkeHUh?=
COR-L88 MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7Vb2FKSzVyPUK2MlU4QTZizszN MWnTRW5ITVJ?
LU-65 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDueZg2UUN3ME2yOk45PTN3IN88US=> MXnTRW5ITVJ?
TGBC1TKB NUDt[3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLyTWM2OD1{Nj65PFI5KM7:TR?= Ml;qV2FPT0WU
THP-1 NYTCSGp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7kelBJUUN3ME2yO{4zOTRzIN88US=> NUXkelhzW0GQR1XS
ONS-76 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL2TWM2OD1{Nz6zN|Ih|ryP M1r0c3NCVkeHUh?=
LC-2-ad MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TadGlEPTB;MkeuOlI{OSEQvF2= NH;Xe2JUSU6JRWK=
EW-13 M33QWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LjWGlEPTB;MkmuNVc1PiEQvF2= NFTINHFUSU6JRWK=
MS-1 M2Dj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TMdWlEPTB;M{CuO|I4QCEQvF2= Mmq4V2FPT0WU
NCI-H2227 NGPoTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\GUJFKSzVyPUOwMlk5ODZizszN M1PESnNCVkeHUh?=
LXF-289 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrmTWM2OD1|MT60OFkzKM7:TR?= MVfTRW5ITVJ?
MC116 NFPjS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLyPIdGUUN3ME2zNk4xQDJ4IN88US=> M1mxcHNCVkeHUh?=
EVSA-T M{XneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLLNodKSzVyPUOyMlI2QDVizszN NX7LeZdzW0GQR1XS
CTB-1 NXPSfYtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P0bGlEPTB;M{OuNVExOSEQvF2= M3G4VXNCVkeHUh?=
COLO-320-HSR NV;mRmM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjzTWM2OD1|Mz6xOlA{KM7:TR?= NFf3d4pUSU6JRWK=
NCI-H2196 M{f2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnmNIh5UUN3ME2zN{4zPTV5IN88US=> M3nl[HNCVkeHUh?=
LB2241-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXvS445UUN3ME2zN{4{OTN3IN88US=> M3vJdXNCVkeHUh?=
LS-513 M{TQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i4fWlEPTB;M{OuPFY{QCEQvF2= MYLTRW5ITVJ?
LP-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTN|Lkm5OVYh|ryP M2i3PXNCVkeHUh?=
A253 M{LL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjYV2lKSzVyPUO0MlIzQTZizszN NXzKb5J4W0GQR1XS
SK-MM-2 M17FZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnpTWM2OD1|ND65OFUyKM7:TR?= NIT0XFVUSU6JRWK=
NCI-H1963 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jOTmlEPTB;M{WuN|A4OiEQvF2= M1u0XnNCVkeHUh?=
MMAC-SF M2D1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTN3Lki3PFUh|ryP NWTlfZhiW0GQR1XS
LB831-BLC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDaTWM2OD1|Nj6wOlU1KM7:TR?= Mnn2V2FPT0WU
WSU-NHL MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTN4LkG2OEDPxE1? Mm\uV2FPT0WU
CESS NIfVdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHKTWM2OD1|Nj6yPFQ5KM7:TR?= M1HreXNCVkeHUh?=
NEC8 NYPQW3gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;zcmlEPTB;M{[uOVg{PSEQvF2= MoHUV2FPT0WU
KNS-42 NYSzdHpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnZNJdTUUN3ME2zO{4yOjN5IN88US=> MX\TRW5ITVJ?
MHH-CALL-2 NWDRZ4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzUTWM2OD1|Nz6xPFIyKM7:TR?= NIrJU4lUSU6JRWK=
K5 M2jOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN6LkSzJO69VQ>? MljjV2FPT0WU
CP66-MEL NInF[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli5TWM2OD1|OT6wO|M{KM7:TR?= NVS4bVJRW0GQR1XS
OPM-2 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHxTVhKSzVyPUO5Mlg1OzJizszN M4i5UHNCVkeHUh?=
IST-MES1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq3d4ZUUUN3ME20NE4{ODl4IN88US=> NXPKTIY{W0GQR1XS
EC-GI-10 M1z0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG1TWM2OD12MT61PFA2KM7:TR?= NWS2dlhkW0GQR1XS
CTV-1 NWjNfVBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLsOHdKSzVyPUSyMlg1ODZizszN MXzTRW5ITVJ?
DG-75 NGrhfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPZb4p[UUN3ME20N{44PTl3IN88US=> MYPTRW5ITVJ?
KNS-81-FD MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzURlJKUUN3ME20OU41ODV6IN88US=> M1fPOnNCVkeHUh?=
NCI-H82 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7CTWM2OD12NT61O|U5KM7:TR?= MVnTRW5ITVJ?
RPMI-8866 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR4LkG4O|Mh|ryP M{fwS3NCVkeHUh?=
ACN M3;OOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK4[ZRnUUN3ME20Ok41OzRizszN M{H1dHNCVkeHUh?=
NCI-H1395 NF\DPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrpe3BKSzVyPUS2MlQ4PTZizszN MoT4V2FPT0WU
NCI-H209 NIT1[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHhNoxKSzVyPUS3MlE1ODVizszN NWnZWHR[W0GQR1XS
TGW M1\5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIixOZpKSzVyPUS5MlA4QTFizszN NHTMdHVUSU6JRWK=
NCI-H748 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTR7LkS3OVMh|ryP NFXYZXlUSU6JRWK=
EKVX MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\MU2lEPTB;NEmuOlYzQCEQvF2= MoHNV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

- Collapse
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 400+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000737 Not yet recruiting Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib Advanced Hepatocellular Carcinoma Yiviva Inc. August 15 2019 Phase 2
NCT03958669 Not yet recruiting -- Hepatocellular Carcinoma|Sorafenib University Hospital Tuebingen|German Federal Ministry of Education and Research July 1 2019 --
NCT03764293 Not yet recruiting Drug: SHR-1210|Drug: Apatinib|Drug: Sorafenib Locally Advanced or Metastatic and Unresectable HCC Jiangsu HengRui Medicine Co. Ltd. January 2019 Phase 3
NCT03582618 Recruiting Drug: Sorafenib|Drug: CVM-1118 Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID